Loading
A US National Cancer Institute network, paid for by the Cancer Moonshot, that works to turn lab discoveries about the immune system into better immunotherapy for adults with cancer and into ways of preventing cancer with the immune system.
The network describes itself as a consortium to accelerate the translation of basic discoveries into clinical applications that improve immunotherapy outcomes, and to prevent cancers before they occur, by drawing on the expertise and resources of a collaborative network to develop improved immunotherapy and immunoprevention approaches, including new combinations. Its project groups, as its site lists them, are cancer immunoprevention, cancer immunotherapy, cancer immuno-engineering and immune-related adverse events, with a cellular immunotherapy data resource and a data management and resource-sharing centre. The NCI's Cancer Moonshot page lists it among the Moonshot's accomplishments as an immuno-oncology translational network to develop immune-based approaches for the treatment and prevention of cancer in adult patients.
Shares No one can predict who responds to immunotherapy and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares No one can predict who responds to immunotherapy and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares Immune-related adverse events (irAEs), No one can predict who responds to immunotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/